Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876070 · ClinicalTrials.gov registry record
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 198
- Enrollment target
NCT00876070 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 198 participants.
The verdict
NCT00876070 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 198 participants
- Enrollment target
Study Summary
This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876070
The ClinicalTrials.gov registry entry for NCT00876070 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00876070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876070 about?
NCT00876070 is a clinical study titled "Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer". This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-lin...
What is the current status of trial NCT00876070?
This trial is currently completed. The enrollment target is 198 participants. The study started on 2008-11. Estimated completion is 2011-02.
Who is sponsoring clinical trial NCT00876070?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.